Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Gubra - video med præsentation af Q1-2025 regnskab

By Claus ThestrupCEO, Sweden
Gubra

Gubra annoncerede fredag den 9 maj 2025 Q1 regnskab. Selskabet fastholder sin guidance for 2025 men ser en nedgang i omsætningen i CRO forretningen YoY. Gubra fremlægger nye spændende data på pipeline kandidaten UCN2 som forventes at gå i klinisk fase i 2026. Alt dette bliver uddybet i dette interview med CEO Henrik Blou samt CFO Kristian Borbos.

Se hele præsentationen her: Gubra Q1-2025

Disclaimer: HC Andersen Capital modtager betaling fra Gubra for en Digital IR abonnementsaftale. /Claus Thestrup kl. 07:32, 12/05/2025.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.